Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.250
-0.150 (-4.41%)
At close: May 15, 2026, 4:00 PM EDT
3.270
+0.020 (0.62%)
After-hours: May 15, 2026, 7:34 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$1,036,550
Market Cap
354.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Puma Biotechnology | 179 |
| Enanta Pharmaceuticals | 120 |
| C4 Therapeutics | 104 |
| Rezolute | 75 |
| Larimar Therapeutics | 71 |
| X4 Pharmaceuticals | 45 |
| Compass Therapeutics | 39 |
RCKT News
- 9 days ago - Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c) - TheFly
- 9 days ago - Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress - Business Wire
- 19 days ago - Rocket Pharmaceuticals announces $180M sale of priority review voucher - TheFly
- 19 days ago - Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher - Business Wire
- 6 weeks ago - Rocket Pharmaceuticals price target raised to $9 from $8 at BofA - TheFly
- 7 weeks ago - Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink - TheFly
- 7 weeks ago - PRV reception could net Rocket $100M-$200M, says LifeSci Capital - TheFly
- 7 weeks ago - Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush - TheFly